The decision to pause dapiglutide will help Zealand focus investment into assets that have “the greatest potential for ...

Unpredictable communication and a lack of transparency are eroding the industry’s and the public’s trust. The FDA, experts ...

The back-heavy deal includes a $5 million upfront payment for two novel T cell engagers, though the companies have yet to ...

Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the ...

In January, AbbVie and Calico’s fosigotifator failed to show significant signs of efficacy in the HEALEY ALS platform trial ...

Korro Bio is moving back to square one as a preclinical biotech after the failure of KRRO-110 in alpha-1 antitrypsin ...

Alixorexton’s Phase II performance sets it up for late-stage success, according to analysts at Truist Securities. Alkermes ...

The plausible mechanism pathway "could accelerate gene therapy/editing development but additional clarity [is] needed," ...

Through substantial leadership turnover and workforce cuts, the FDA has continued to support the advanced therapy sector, actively working to remove obstacles to innovation.

While most BioSpace LinkedIn poll respondents believe the job market won’t improve until at least 2027, two industry experts ...

One of the FDA’s potential approvals this month could break an existing monopoly in the treatment space for a rare growth ...

In this episode presented by Slone Partners, Leslie Loveless, Co-CEO and Managing Partner discusses how hiring and the ...